1
Patient safety is non-negotiable — it governs every clinical and strategic decision.
Our FirmScience-Driven Strategy.
Science-Driven Strategy.
AI-Augmented Execution.
MindPath Pharma Consulting combines 25+ years of physician-executive drug development expertise with state-of-the-art AI research capabilities — delivering the strategic depth of a senior CMO and the analytical throughput of a full team, to every engagement.
MD, PhD, MPH
Physician-Scientist
CMO / Head of R&D
C-Suite Biotech Leadership
NIH/NIDA Grants
Competitive Non-Dilutive Funding
25+ Years
Healthcare & Drug Development
Founder
A Career at the Intersection of Science, Medicine & Strategy
Bruce Imbert, MD, PhD, MPH is a physician-scientist and drug development executive with more than 25 years of experience spanning academia, government, Big Pharma, biotech, and digital health.
He has held senior leadership positions including Chief Medical Officer, Head of R&D, and VP of Clinical Development at organizations ranging from early-stage startups to global pharmaceutical companies, leading programs from IND through NDA approval.
His clinical and scientific work centers on CNS drug development, addiction medicine, and psychiatry — with particular expertise in opioid use disorder, alcohol use disorder, and the regulatory science of novel CNS mechanisms.
MindPath Pharma Consulting is a parallel track alongside ongoing C-suite work. Engagements are accepted when capacity allows, and are screened for conflicts before any proprietary exchange.
Career Milestones
Selected Highlights
Regulatory Submissions & Approvals
IND filings, NDA approvals, and EU Marketing Authorization across CNS and OUD programs
FDA-Authorized PDTs
reSET® & reSET-O® — first in class, Pear Therapeutics
NIH/NIDA & Inserm-ANRS Grants
Principal Investigator & Co-Investigator on multiple competitive federal grants (US & France)
Global Strategy & FDA Submissions
Senior Leadership Team, Indivior — CNS/OUD portfolio at scale
ATX-1209 IND Program
First-in-class dependence modulator, Aether Therapeutics
Fast Track Designation
FDA Fast Track filing and alignment, SUD indications
mGluR5 NAM Patents
Novel therapeutic approaches for substance use disorder
Peer-Reviewed Publications
International scientific journals across addiction medicine, clinical pharmacology, and digital health
How We Work
Senior Expertise Across All Engagements
2
Every claim must trace to evidence: published data, regulatory precedent, or clearly labeled expert interpretation.
3
Indication-specific strategy — reflecting the MOA, patient population, and regulatory landscape, not a generic template.
4
Small, well-designed trials can be decisive — we do not default to large trials when a focused design answers the question.
5
Real-world evidence is a legitimate and underutilized source — we integrate it alongside RCT data.
6
Every deliverable ends with actionable conclusions — a clear recommendation or defined next step.
Work With a Senior Development Partner
Every engagement is handled personally — no junior staff, no templated deliverables. Your program gets the same rigor applied to a pivotal trial or regulatory submission.
Start a Conversation